Drug Information

Drug General Information
Drug ID
D0PY3L
Former ID
DNCL002165
Drug Name
MEDI-565
Drug Type
Monoclonal antibody
Indication Gastrointestinal adenocarcinoma [ICD10:C15-C26] Phase 1 [523334]
Company
MedImmune
Target and Pathway
Target(s) CD3 Target Info Modulator [889442]
KEGG Pathway Hematopoietic cell lineage
T cell receptor signaling pathway
Chagas disease (American trypanosomiasis)
Measles
HTLV-I infection
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway T cell activation
Pathway Interaction Database TCR signaling in na&#xef
IL12-mediated signaling events
TCR signaling in na&#xef
CXCR4-mediated signaling events
Downstream signaling in na&#xef
IL12 signaling mediated by STAT4
Reactome Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Phosphorylation of CD3 and TCR zeta chains
Translocation of ZAP-70 to Immunological synapse
Generation of second messenger molecules
FCGR activation
Regulation of actin dynamics for phagocytic cup formation
Role of phospholipids in phagocytosis
PD-1 signaling
WikiPathways TCR Signaling Pathway
Fcgamma receptor (FCGR) dependent phagocytosis
TCR signaling
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Costimulation by the CD28 family
References
Ref 523334ClinicalTrials.gov (NCT01284231) A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas. U.S. National Institutes of Health.
Ref 889442Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. doi: 10.1038/nrd4478.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.